
The team of scientists at the Montreal Clinical Research Institute (IRCM), led by Javier Di Noia.
Photo Credit: IRCM
Scientific Frontline: Extended "At a Glance" Summary: Immune System Targeting of Antibody Mutations
The Core Concept: B cells modify their own DNA using the mutagenic enzyme activation-induced cytidine deaminase (AID) to produce a vast diversity of antibodies, a process guided safely by the proteins MLLT1 and MLLT3.
Key Distinction/Mechanism: Unlike uncontrolled genome mutation, the proteins MLLT1 and MLLT3 recognize specific chemical marks on histones and form microscopic molecular condensates; these compartments physically concentrate the naturally inefficient AID enzyme exactly where it is needed, largely sparing the rest of the genome from damage.
Major Frameworks/Components:
- Activation-induced cytidine deaminase (AID): An essential but potentially dangerous enzyme that introduces mutations into antibody genes to improve immune effectiveness.
- MLLT1 and MLLT3 proteins: Histone readers that act as gatekeepers to direct and control AID activity.
- Molecular condensates: Tiny compartments formed by MLLT1 and MLLT3 that gather AID locally to increase the likelihood of targeted mutation.
- Histones: The structural proteins around which DNA is wrapped, providing the chemical markers recognized by the gatekeeper proteins.



.jpg)


.png)



.png)

